The FDA has placed a partial clinical hold on Cell Therapeutics's (NASDAQ:CTIC) tosedostat blood cancer drug following the death of a patient in a trial in which the treatment was given along with chemotherapy. The patient died of myocarditis, or infection of the heart muscle. The agency has asked for more information about any heart issues in subjects treated with tosedostat. (8-K)